CIBC set a C$6.00 price target on kneat.com (TSE:KSI - Free Report) in a report released on Tuesday, BayStreet.CA reports. The brokerage currently has an outperform rating on the stock.
Separately, Ventum Cap Mkts raised shares of kneat.com to a "strong-buy" rating in a report on Wednesday, August 7th.
View Our Latest Research Report on kneat.com
kneat.com Stock Performance
Shares of TSE:KSI traded up C$0.02 during trading on Tuesday, hitting C$4.77. 61,458 shares of the company traded hands, compared to its average volume of 56,099. The stock has a market capitalization of C$410.22 million, a price-to-earnings ratio of -29.81, a PEG ratio of 597.67 and a beta of 1.08. kneat.com has a one year low of C$2.68 and a one year high of C$5.17. The company has a quick ratio of 1.50, a current ratio of 1.47 and a debt-to-equity ratio of 95.14. The business's fifty day moving average is C$4.76 and its 200-day moving average is C$4.44.
kneat.com (TSE:KSI - Get Free Report) last released its quarterly earnings results on Tuesday, August 6th. The company reported C($0.04) EPS for the quarter, hitting the consensus estimate of C($0.04). The business had revenue of C$11.68 million during the quarter, compared to analyst estimates of C$11.45 million. kneat.com had a negative net margin of 31.19% and a negative return on equity of 51.13%. As a group, equities analysts predict that kneat.com will post -0.12 earnings per share for the current fiscal year.
About kneat.com
(
Get Free Report)
kneat.com, inc., together with its subsidiaries, designs, develops, and supplies software for data and document management within regulated environments in North America, Europe, and the Asia Pacific. The company offers the Kneat Gx platform, a configurable off-the-shelf application focused on validation lifecycle management and testing for biotechnology, pharmaceutical, and medical device manufacturing industries.
See Also
Before you consider kneat.com, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and kneat.com wasn't on the list.
While kneat.com currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
